亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

33553 Real-world treatment patterns and outcomes up to 1 year among children aged <12 years with moderate-to-severe atopic dermatitis (AD) enrolled in the PEDIatric STudy in Atopic Dermatitis (PEDISTAD) observational study

医学 特应性皮炎 湿疹面积及严重程度指数 杜皮鲁玛 皮肤科生活质量指数 甲氨蝶呤 生活质量(医疗保健) 体表面积 儿科 皮肤病科 斯科拉德 内科学 银屑病 护理部
作者
Eulàlia Baselga,Nikolay N. Murashkin,Myong Soon Sung,Lara Wine Lee,Chunyuan Liu,Lauren Bates,Annie Zhang
出处
期刊:Journal of The American Academy of Dermatology [Elsevier BV]
卷期号:87 (3): AB200-AB200
标识
DOI:10.1016/j.jaad.2022.06.831
摘要

Background: We describe real-world treatment patterns in patients aged <12 years with moderate-to-severe AD, focusing on systemic treatments. Methods: PEDISTAD (NCT03687359) is an ongoing, international, noninterventional registry in patients aged <12 years with moderate-to-severe AD inadequately controlled with topical therapies. Treatment was per investigator discretion. In this interim analysis (data cutoff 30 July 2020), we report baseline data for all patients, and changes in the following outcomes (from therapy start [TS] to last observation [LO]) for patients receiving systemic treatments of interest (dupilumab, cyclosporine, or methotrexate): Eczema Area and Severity Index (EASI), AD-affected body surface area (BSA), Patient-Oriented Eczema Measure (POEM), Children’s Dermatology Life Quality Index (CDLQI; 4–<12 years), and current-day peak pruritus numerical rating scale (PP-NRS). No formal statistical testing was performed. Results: At baseline, 77.2% (565/732) of patients were receiving nonsystemic AD therapies (topical corticosteroids: 69.9%); 23.1% were receiving systemic therapies, including: dupilumab: 2.6% [n = 19]; cyclosporine: 8.1% [n = 59]; and methotrexate: 9.0% [n = 66]. The median duration of patient follow-up was 8.7 months. Physician-reported outcomes (change in mean ± SD) improved from TS to LO: EASI (dupilumab [n = 31], cyclosporine [n = 80], methotrexate [n = 69]: -13.8 ± 15.4, -4.6 ± 12.2, -6.2 ± 12.8) and % BSA (-18.4 ± 25.0, -13.6 ± 22.3, -14.6 ± 18.8). Change in patient/caregiver-reported outcomes were: POEM (-7.6 ± 8.5, -2.1 ± 11.1, -4.3 ± 11.2), CDLQI (-7.2 ± 7.8, 0.3 ± 5.5, -2.9 ± 6.8) and PP-NRS (-2.6 ± 2.3, 0.7 ± 3.0, 0.6 ± 2.5). Time-to-discontinuation (mean ± SD, months) was: dupilumab (8.6 ± 6.4); cyclosporine (5.2 ± 4.1); methotrexate (7.0 ± 4.7). Conclusions: The most common treatment at baseline for children aged <12 years with moderate-to-severe AD was topical corticosteroids. Dupilumab was associated with greater improvements in clinical assessments/patient-reported outcomes vs other systemic therapies.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
6秒前
15秒前
嘟嘟嘟嘟完成签到 ,获得积分10
19秒前
Zhy完成签到,获得积分10
24秒前
量子星尘发布了新的文献求助10
25秒前
科研通AI2S应助科研通管家采纳,获得10
31秒前
33秒前
lf发布了新的文献求助10
33秒前
lei029发布了新的文献求助10
39秒前
43秒前
44秒前
Tonyzad完成签到,获得积分10
47秒前
He发布了新的文献求助20
49秒前
江洋大盗发布了新的文献求助10
49秒前
CATH完成签到 ,获得积分10
51秒前
lei029完成签到,获得积分10
56秒前
kingJames发布了新的文献求助10
1分钟前
kingJames完成签到,获得积分10
1分钟前
慕青应助555557采纳,获得10
1分钟前
迷路的八宝粥完成签到,获得积分10
1分钟前
He完成签到,获得积分10
1分钟前
休眠补正完成签到,获得积分10
1分钟前
1分钟前
snoke发布了新的文献求助30
1分钟前
李健应助太清采纳,获得10
1分钟前
1分钟前
歪歪完成签到 ,获得积分10
1分钟前
江洋大盗发布了新的文献求助10
2分钟前
黄庆勇发布了新的文献求助10
2分钟前
DPH完成签到 ,获得积分10
2分钟前
2分钟前
斯文败类应助susu采纳,获得10
2分钟前
两栖玩家完成签到 ,获得积分10
2分钟前
snoke完成签到,获得积分10
2分钟前
量子星尘发布了新的文献求助10
2分钟前
2分钟前
nanfang完成签到 ,获得积分10
2分钟前
2分钟前
2分钟前
2分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976619
求助须知:如何正确求助?哪些是违规求助? 3520720
关于积分的说明 11204567
捐赠科研通 3257359
什么是DOI,文献DOI怎么找? 1798716
邀请新用户注册赠送积分活动 877897
科研通“疑难数据库(出版商)”最低求助积分说明 806613